Roadside Drug Testing Devices are used to identify the existence of drug or their metabolites in a person’s body through studying biological samples including hair, blood, & urine, etc. The increasing road accidents due to the drink & drive scenario and increasingly becoming a matter of concern for government authorities across the globe are expected to drive the growth of the roadside drug testing devices market during the forecast period. For instance, according to the National Highway Traffic Safety Administration, every day around 28 people die in drunk & driving crashes in the US.

Moreover, consistent with these cases healthcare industry will launch innovative products and are generating incremental opportunities for companies in the roadside drug testing devices market. For instance, Abbott Laboratories launched the SoToxa Mobile Test System in December 2019. This system is a novel roadside drug testing device and aimed to gain importance to combat drug-impaired driving and ensure road safety.

The global Roadside Drug Testing Devices market was valued at USD 980.4 million in 2020, growing with 4.6?GR during the forecast period, 2021-2027. North America is expected to hold the largest market share of the roadside drug testing devices market during the forecast period. The growth in the region is attributed to the increase in late-night pubs and drinking bars for amusements contributing the drink-related accidents. For instance, according to the Centers for Disease Control and Prevention (CDC), around 4.7% of people aged 16 years or above in the U.S. are reported to be driving under the influence of marijuana and 0.9% are reported to be driving under the influence of illicit drugs other than marijuana.

Besides, Europe will also contribute generously due to its rising rising student union clubs and night pubs. Additionally, growing preference amongst new generation youths to weekend club parties and adoption to western culture will also increase the market of roadside drug testing devices market. 

In October 2017, Abbott Laboratories acquired Alere, Inc. for about USD 4.5 billion. The acquisition bolstered the company’s product portfolio in the point of care testing devices and solutions segment. SoToxa previously referred to as the Alere DDS2 mobile test system, is capable of generating test results indicating the presence of certain drugs in only 5 minutes. SoToxa is presently being utilized by regulation enforcement corporations in countries across the world such as Canada, Germany, Spain, the U.K., and the U.S.

Read More: 

Tags: Lifeloc, Oranoxis, MAVAND Solutions GmbH, Alcohol Testing, Drug Testing, Abbott

See Campaign:

Contact Information:

Global Information, Inc. (JASDAQ 4171) Toll Free (US): +1-866-353-3335 Outside US: +1-860-674-8796 Europe (Belgium): +32-2-535-7543 Email: [email protected]

PR-Wirein, Financial Content, Reportedtimes, Extended Distribution, iCN Internal Distribution, Research Newswire, English